Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling

被引:62
作者
Altinok, Atilla [1 ]
Levi, Francis [2 ,3 ,4 ]
Goldbeter, Albert [1 ]
机构
[1] Univ Libre Bruxelles, Fac Sci, Unite Chronobiol Theor, B-1050 Brussels, Belgium
[2] INSERM, U776, F-94807 Villejuif, France
[3] Univ Paris Sud, UMR S0776, F-91405 Orsay, France
[4] Hop Paul Brousse, AP HP, Dept Cancerol, Unite Chronotherapie, F-94807 Villejuif, France
关键词
Circadian Rhythms; Glutathione; Chronotolerance; Cell Cycle; Cancer Chronotherapy; Model; DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; CIRCADIAN-RHYTHM; FOLINIC ACID; PLASMA-CONCENTRATION; POSSIBLE RELEVANCE; ENZYME-ACTIVITY; MOUSE-LIVER; CLOCKS; TOXICITY; DELIVERY;
D O I
10.1016/j.ejps.2008.10.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We use an automaton model for the cell cycle to assess the toxicity of various circadian patterns of anticancer drug delivery so as to enhance the efficiency of cancer chronotherapy. Based on the sequential transitions between the successive phases G1, S (DNA replication), G2, and M (mitosis) of the cell cycle, the model allows us to simulate the distribution of cell cycle phases as well as entrainment by the circadian clock. We use the model to evaluate circadian patterns of administration of two anticancer drugs, S-fluorouracil (5-FU) and oxaliplatin (l-OHP). We first consider the case of 5-FU, which exerts its cytotoxic effects on cells in S phase. We compare various circadian patterns of drug administration differing by the time of maximum drug delivery. The model explains why minimum cytotoxicity is obtained when the time of peak delivery is close to 4 a.m., which temporal pattern of drug administration is used clinically for 5-FU. We also determine how cytotoxicity is affected by the variability in duration of cell cycle phases and by cell cycle length in the presence or absence of entrainment by the circadian clock. The results indicate that the same temporal pattern of drug administration can have minimum cytotoxicity toward one cell population, e.g. of normal cells, and at the same time can display high cytotoxicity toward a second cell population, e.g. of tumour cells. Thus the model allows us to uncover factors that may contribute to improve simultaneously chronotolerance and chronoefficacy of anticancer drugs. We next consider the case of oxaliplatin, which, in contrast to 5-FU, kills cells in different phases of the cell cycle. We incorporate into the model the pharmacokinetics of plasma thiols and intracellular glutathione, which interfere with the action of the drug by forming with it inactive complexes. The model shows how circadian changes in l-OHP cytotoxicity may arise from circadian variations in the levels of plasma thiols and glutathione. Corroborating experimental and clinical results, the simulations of the model account for the observation that the temporal profiles minimizing l-OHP cytotoxicity are in antiphase with those minimizing cytotoxicity for 5-FU. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:20 / 38
页数:19
相关论文
共 54 条
  • [41] Peters G J, 1987, In Vivo, V1, P113
  • [42] PETIT E, 1988, CANCER RES, V48, P1676
  • [43] Popovic P, 1982, Prog Clin Biol Res, V107, P185
  • [44] Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver:: comparison between enzyme activity and gene expression
    Porsin, B
    Formento, JL
    Filipski, E
    Etienne, MC
    Francoual, M
    Renée, N
    Magné, N
    Lévi, F
    Milano, G
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) : 822 - 828
  • [45] Circadian clocks: Neural and peripheral pacemakers that impact upon the cell division cycle
    Reddy, AB
    Wong, GKY
    O'Neill, J
    Maywood, ES
    Hastings, MH
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 574 (1-2) : 76 - 91
  • [46] Redfern R, 2003, CHRONOTHERAPEUTICS, P235
  • [47] Rhythms in human bone marrow and blood cells
    Smaaland, R
    Sothern, RB
    Laerum, OD
    Abrahamsen, JF
    [J]. CHRONOBIOLOGY INTERNATIONAL, 2002, 19 (01) : 101 - 127
  • [48] DO CELLS CYCLE
    SMITH, JA
    MARTIN, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (04) : 1263 - 1267
  • [49] Tampellini M, 1998, CANCER RES, V58, P3896
  • [50] Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells
    Voland, Carole
    Bord, Annie
    Peleraux, Annick
    Penarier, Geraldine
    Carriere, Dominique
    Galiegue, Sylvaine
    Cvitkovic, Esteban
    Jbilo, Omar
    Casellas, Pierre
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (09) : 2149 - 2157